Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Mr. Spencer S. StilesPresident & COO | -1,61k | 0,00 | Other Disposition | - | 77,72k | -2,03% |
| 2026-05-28 | Mr. Robert S. FletcherVP & Chief Legal Officer | -4,54k | 1,39M | Automatic Disposition | 304,23 - 310,22 | 10,77k | -29,68% |
| 2026-05-26 | Ms. Ronda E. StrykerIndependent Director | -310,00k | 96,79M | Vente | 310,77 - 315,11 | 14,82M | -2,05% |
| 2026-05-11 | Ms. M. Kathryn FinkVP & Chief HR Officer | -3,50k | 992,09k | Vente | 283,45 | 12,84k | -21,42% |
| 2026-05-08 | Ms. M. Kathryn FinkVP & Chief HR Officer | -21,58k | 2,67M | Derivative Exercise and Sale | 154,14 - 294,23 | 12,84k | - |
| 2026-03-21 | Mr. Spencer S. StilesPresident & COO | -430,00 | 144,34k | Derivative Exercise and Sale | 335,67 | 79,30k | - |
| 2026-03-21 | Mr. Spencer S. StilesPresident & COO | -6,26k | 2,10M | Sale to Issuer | 335,67 | 79,30k | -7,32% |
| 2026-03-21 | Mr. J. Andrew PierceGroup President of MedSurg & Neurotechnology | -430,00 | 144,34k | Derivative Exercise and Sale | 335,67 | 81,12k | - |
| 2026-03-21 | Mr. J. Andrew PierceGroup President of MedSurg & Neurotechnology | -7,38k | 2,48M | Sale to Issuer | 335,67 | 81,12k | -8,34% |
| 2026-03-21 | Mr. Viju S. MenonGroup President of Global Quality & Operations | -269,00 | 90,30k | Derivative Exercise and Sale | 335,67 | 17,58k | - |
| 2026-03-21 | Mr. Viju S. MenonGroup President of Global Quality & Operations | -4,45k | 1,49M | Sale to Issuer | 335,67 | 17,58k | -20,20% |
| 2026-03-21 | Mr. Kevin A. LoboChairman & CEO | -1,45k | 487,39k | Derivative Exercise and Sale | 335,67 | 222,95k | - |
| 2026-03-21 | Mr. Kevin A. LoboChairman & CEO | -25,04k | 8,41M | Sale to Issuer | 335,67 | 222,95k | -10,10% |
| 2026-03-21 | Mr. Robert S. FletcherVP & Chief Legal Officer | -225,00 | 75,53k | Derivative Exercise and Sale | 335,67 | 15,29k | - |
| 2026-03-21 | Mr. Robert S. FletcherVP & Chief Legal Officer | -3,16k | 1,06M | Sale to Issuer | 335,67 | 15,29k | -17,12% |
| 2026-03-21 | Ms. M. Kathryn FinkVP & Chief HR Officer | -150,00 | 50,35k | Derivative Exercise and Sale | 335,67 | 16,32k | - |
| 2026-03-21 | Ms. M. Kathryn FinkVP & Chief HR Officer | -1,91k | 642,47k | Sale to Issuer | 335,67 | 16,32k | -10,50% |
| 2026-03-21 | Mr. Preston W. WellsVP & CFO | -204,00 | 68,48k | Sale to Issuer | 335,67 | 6,79k | -2,92% |
| 2026-03-21 | Mr. Dylan B. CrottyGroup President of Orthopaedics | -368,00 | 123,53k | Sale to Issuer | 335,67 | 14,12k | -2,54% |
| 2026-03-21 | Mr. William E. BerryVP & CAO | -176,00 | 59,08k | Sale to Issuer | 335,67 | 1,23k | -12,49% |
| 2026-02-23 | Ms. Ronda E. StrykerIndependent Director | -55,60k | 0,00 | Other Disposition | - | 15,13M | -0,37% |
| 2026-02-13 | Ms. Ronda E. StrykerIndependent Director | -642,20k | 0,00 | Other Disposition | - | 15,18M | -4,06% |
| 2026-02-04 | Ms. Ronda E. StrykerIndependent Director | -500,00k | 181,72M | Vente | 358,51 - 368,56 | 15,82M | -3,06% |
| 2026-02-06 | Mr. Kevin A. LoboChairman & CEO | 74,55k | 7,20M | Derivative Exercise and Retained Stock | 96,64 | 197,66k | 60,55% |
| 2026-02-06 | Mr. Kevin A. LoboChairman & CEO | -132,41k | 35,19M | Derivative Exercise and Sale | 96,64 - 362,42 | 197,66k | - |
| 2026-02-03 | Mr. Spencer S. StilesPresident & COO | 6,15k | 594,14k | Derivative Exercise and Retained Stock | 96,64 | 70,65k | 9,53% |
| 2026-02-03 | Mr. Spencer S. StilesPresident & COO | -7,69k | 2,09M | Derivative Exercise and Sale | 96,64 - 368,14 | 70,65k | - |
| 2026-02-02 | Mr. J. Andrew PierceGroup President of MedSurg & Neurotechnology | 4,93k | 476,73k | Derivative Exercise and Retained Stock | 96,64 | 73,58k | 7,19% |
| 2026-02-02 | Mr. J. Andrew PierceGroup President of MedSurg & Neurotechnology | -8,91k | 2,43M | Derivative Exercise and Sale | 96,64 - 369,56 | 73,58k | - |
| 2026-01-15 | Mr. Andrew K. SilvernailIndependent Director | 3,34k | 322,87k | Derivative Exercise and Retained Stock | 96,64 | 12,69k | 35,74% |
| 2026-01-15 | Mr. Andrew K. SilvernailIndependent Director | -1,23k | 322,92k | Derivative Exercise and Sale | 96,64 - 359,39 | 12,69k | - |
| 2026-01-14 | Ms. Ronda E. StrykerIndependent Director | 4,57k | 441,64k | Derivative Exercise and Retained Stock | 96,64 | 16,32M | 0,03% |
| 2025-12-16 | Ms. M. Kathryn FinkVP & Chief HR Officer | -37,00 | 13,15k | Sale to Issuer | 355,31 | 13,01k | -0,28% |
| 2025-12-16 | Mr. William E. BerryVP & CAO | -28,00 | 9,95k | Sale to Issuer | 355,31 | 829,00 | -3,27% |
| 2025-11-21 | Mr. J. Andrew PierceGroup President of MedSurg & Neurotechnology | -211,00 | 0,00 | Other Disposition | - | 68,65k | -0,31% |
| 2025-11-20 | Mr. Preston W. WellsVP & CFO | -165,00 | 60,37k | Vente | 365,88 | 6,98k | -2,31% |
| 2025-11-14 | Mr. William E. BerryVP & CAO | -4,93k | 1,06M | Derivative Exercise and Sale | 154,14 - 373,42 | 613,00 | - |
| 2025-11-05 | Ms. Ronda E. StrykerIndependent Director | -520,00k | 184,61M | Vente | 349,95 - 359,79 | 16,32M | -3,09% |
| 2025-11-01 | Mr. Preston W. WellsVP & CFO | -404,00 | 143,92k | Sale to Issuer | 356,24 | 7,15k | -5,35% |
| 2025-08-25 | Mr. Viju S. MenonGroup President of Global Quality & Operations | -500,00 | 195,31k | Vente | 390,61 | 12,71k | -3,79% |
| 2025-08-20 | Mr. Robert S. FletcherVP & Chief Legal Officer | -1,79k | 701,63k | Vente | 393,07 | 10,62k | -14,39% |
| 2025-08-06 | Ms. Ronda E. StrykerIndependent Director | -200,00k | 75,29M | Vente | 374,99 - 381,13 | 16,84M | -1,17% |
| 2025-08-01 | Kimberly Ann MontagninoInitié | -155,00 | 60,87k | Sale to Issuer | 392,73 | 1,21k | -11,37% |
| 2025-08-01 | Mr. Robert S. FletcherVP & Chief Legal Officer | -441,00 | 173,19k | Sale to Issuer | 392,73 | 12,40k | -3,43% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
